Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Examination of Online Direct-to-Consumer Prescription Drug Promotion, 42500-42501 [2012-17554]
Download as PDF
42500
Federal Register / Vol. 77, No. 139 / Thursday, July 19, 2012 / Notices
ESTIMATED ANNUALIZED BURDEN TABLE
Number of
responses per
respondent
Number of
respondents
Average
burden per
response
(hours)
Total burden
(hours)
Form name
Type of respondent
Think Cultural Health Registration
Form.
Physician ..........................................
27477
1
3/60
1,373.85
Nurse ................................................
Physician Assistant ..........................
Dentist ..............................................
Dental Professional ..........................
Social Worker ...................................
Public Health ....................................
General Healthcare Worker .............
Psychologist/Psychiatrist ..................
Mental Health Professional ..............
Pharmacist, RPH ..............................
Emergency Medical Technician .......
Administrator or Hospital Executive
Policymaker or Public Official ..........
Teacher ............................................
Lawyer ..............................................
Bachelors .........................................
Masters .............................................
Doctorate ..........................................
Student .............................................
Other ................................................
44723
1882
377
39
1733
186
12635
189
180
750
492
151
17
424
107
3753
4063
1130
7504
10880
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
3/60
3/60
3/60
3/60
3/60
3/60
3/60
3/60
3/60
3/60
3/60
3/60
3/60
3/60
3/60
3/60
3/60
3/60
3/60
3/60
2,236.15
94.10
18.85
1.95
86.65
9.30
631.75
9.45
9.00
37.50
24.60
7.55
0.85
21.20
5.35
187.65
203.15
56.50
375.20
544.00
118692 .............................................
1
3/60
5,934.60
Total ...........................................
Keith A. Tucker,
Office of the Secretary, Paperwork Reduction
Act Clearance Officer.
[FR Doc. 2012–17489 Filed 7–18–12; 8:45 am]
BILLING CODE 4150–29–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Designation of a Class of Employees
for Addition to the Special Exposure
Cohort; Correction
National Institute for
Occupational Safety and Health
(NIOSH), Centers for Disease Control
and Prevention, Department of Health
and Human Services (HHS).
ACTION: Notice; correction.
AGENCY:
HHS published a notice in the
Federal Register (Volume 77, Number
130, Page 40059) on July 6, 2012 to give
notice of a decision to designate a class
of employees from the Feed Materials
Production Center (FMPC) in Fernald,
Ohio, also known as the Fernald
Environmental Management Project
(FEMP), as an addition to the Special
Exposure Cohort (SEC) under the Energy
Employees Occupational Illness
Compensation Program Act of 2000. The
designation was incorrect. Therefore,
HHS has published this notice of
correction. On June 27, 2012, the
Secretary of HHS designated the
following class of employees as an
addition to the SEC:
emcdonald on DSK67QTVN1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
17:10 Jul 18, 2012
Jkt 226001
All employees of DOE, its predecessor
agencies, and their contractors, or
subcontractors who worked at the Feed
Materials Production Center (FMPC) in
Fernald, Ohio, from January 1, 1968 through
December 31, 1978, for a number of work
days aggregating at least 250 work days,
occurring either solely under this
employment, or in combination with work
days within the parameters established for
one or more other classes of employees
included in the Special Exposure Cohort.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
The designation published in this
notice of correction will become
effective on July 27, 2012, unless
Congress provides otherwise prior to the
effective date. After this effective date,
HHS will publish a notice in the
Federal Register reporting the addition
of this class to the SEC or the result of
any provision by Congress regarding the
decision by HHS to add the class to the
SEC.
AGENCY:
FOR FURTHER INFORMATION CONTACT:
Stuart L. Hinnefeld, Director, Division
of Compensation Analysis and Support,
NIOSH, 4676 Columbia Parkway, MS C–
46, Cincinnati, OH 45226, Telephone 1–
877–222–7570. Information requests can
also be submitted by email to
DCAS@CDC.GOV.
John Howard,
Director, National Institute for Occupational
Safety and Health.
[FR Doc. 2012–17569 Filed 7–18–12; 8:45 am]
BILLING CODE 4163–19–P
PO 00000
Frm 00019
Fmt 4703
Sfmt 4703
Food and Drug Administration
[Docket No. FDA–2011–N–0230]
Agency Information Collection
Activities; Announcement of Office of
Management and Budget Approval;
Examination of Online Direct-toConsumer Prescription Drug
Promotion
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing
that a collection of information entitled
‘‘Examination of Online Direct-toConsumer Prescription Drug
Promotion’’ has been approved by the
Office of Management and Budget
(OMB) under the Paperwork Reduction
Act of 1995.
FOR FURTHER INFORMATION CONTACT:
Juanmanuel Vilela, Office of
Information Management, Food and
Drug Administration, 1350 Piccard Dr.,
PI50–400B, Rockville, MD 20850, 301–
796–7651,
Juanmanuel.Vilela@fda.hhs.gov.
SUMMARY:
On
January 31, 2012, the Agency submitted
a proposed collection of information
entitled ‘‘Examination of Online Directto-Consumer Prescription Drug
SUPPLEMENTARY INFORMATION:
E:\FR\FM\19JYN1.SGM
19JYN1
Federal Register / Vol. 77, No. 139 / Thursday, July 19, 2012 / Notices
Promotion’’ to OMB for review and
clearance under 44 U.S.C. 3507. An
Agency may not conduct or sponsor,
and a person is not required to respond
to, a collection of information unless it
displays a currently valid OMB control
number. OMB has now approved the
information collection and has assigned
OMB control number 0910–0714. The
approval expires on July 31, 2015. A
copy of the supporting statement for this
information collection is available on
the Internet at https://www.reginfo.gov/
public/do/PRAMain.
Dated: July 12, 2012.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2012–17554 Filed 7–18–12; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2012–N–0248]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Guidance for
Industry on Formal Dispute
Resolution; Appeals Above the
Division Level
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the
collection of information by August 20,
2012.
ADDRESSES: To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, FAX:
202–395–7285, or emailed to
oira_submission@omb.eop.gov. All
comments should be identified with the
OMB control number 0910–0430. Also
include the FDA docket number found
in brackets in the heading of this
document.
emcdonald on DSK67QTVN1PROD with NOTICES
SUMMARY:
FOR FURTHER INFORMATION CONTACT:
Juanmanuel Vilela, Office of
Information Management, Food and
Drug Administration, 1350 Piccard Dr.,
PI50–400B, Rockville, MD 20850, 301–
VerDate Mar<15>2010
15:07 Jul 18, 2012
Jkt 226001
796–7651,
juanmanuel.vilela@fda.hhs.gov.
In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
collection of information to OMB for
review and clearance.
SUPPLEMENTARY INFORMATION:
Guidance for Industry on Formal
Dispute Resolution; Appeals Above the
Division Level—(OMB Control Number
0910–0430)—(Extension)
This information collection approval
request is for FDA guidance on the
process for formally resolving scientific
and procedural disputes in the Center
for Drug Evaluation and Research
(CDER) and the Center for Biologics
Evaluation and Research (CBER) that
cannot be resolved at the division level.
The guidance describes procedures for
formally appealing such disputes to the
office or center level and for submitting
information to assist center officials in
resolving the issue(s) presented. The
guidance provides information on how
the Agency will interpret and apply
provisions of the existing regulations
regarding internal Agency review of
decisions (§ 10.75 (21 CFR 10.75)) and
dispute resolution during the
investigational new drug (IND) process
(§ 312.48 (21 CFR 312.48)) and the new
drug application/abbreviated new drug
application (NDA/ANDA) process
(§ 314.103 (21 CFR 314.103)). In
addition, the guidance provides
information on how the Agency will
interpret and apply the specific
Prescription Drug User Fee Act
(PDUFA) goals for major dispute
resolution associated with the
development and review of PDUFA
products.
Existing regulations, which appear
primarily in 21 CFR parts 10, 312, and
314, establish procedures for the
resolution of scientific and procedural
disputes between interested persons and
the Agency, CDER, and CBER. All
Agency decisions on such matters are
based on information in the
administrative file (§ 10.75(d)). In
general, the information in an
administrative file is collected under
existing regulations in part 312 (OMB
control number 0910–0014), part 314
(OMB control number 0910–0001), and
part 601 (21 CFR part 601) (OMB control
number 0910–0338), which specify the
information that manufacturers must
submit so that FDA may properly
evaluate the safety and effectiveness of
drugs and biological products. This
information is usually submitted as part
of an IND, NDA, or biologics license
application (BLA), or as a supplement to
an approved application. While FDA
PO 00000
Frm 00020
Fmt 4703
Sfmt 4703
42501
already possesses in the administrative
file the information that would form the
basis of a decision on a matter in
dispute resolution, the submission of
particular information regarding the
request itself and the data and
information relied on by the requestor
in the appeal would facilitate timely
resolution of the dispute. The guidance
describes the following collection of
information not expressly specified
under existing regulations: The
submission of the request for dispute
resolution as an amendment to the
application for the underlying product,
including the submission of supporting
information with the request for dispute
resolution.
Agency regulations (§§ 312.23(11)(d),
314.50, 314.94, and 601.2) state that
information provided to the Agency as
part of an IND, NDA, ANDA, or BLA is
to be submitted in triplicate and with an
appropriate cover form. Form FDA 1571
must accompany submissions under
INDs and Form FDA 356h must
accompany submissions under NDAs,
ANDAs, and BLAs. Both forms have
valid OMB control numbers as follows:
FDA Form 1571—OMB control number
0910–0014, and FDA Form 356h—OMB
control number 0910–0338.
In the guidance document, CDER and
CBER ask that a request for formal
dispute resolution be submitted as an
amendment to the application for the
underlying product and that it be
submitted to the Agency in triplicate
with the appropriate form attached,
either Form FDA 1571 or Form FDA
356h. The Agency recommends that a
request be submitted as an amendment
in this manner for two reasons: To
ensure that each request is kept in the
administrative file with the entire
underlying application and to ensure
that pertinent information about the
request is entered into the appropriate
tracking databases. Use of the
information in the Agency’s tracking
databases enables the appropriate
Agency official to monitor progress on
the resolution of the dispute and to
ensure that appropriate steps will be
taken in a timely manner.
CDER and CBER have determined and
the guidance recommends that the
following information should be
submitted to the appropriate center with
each request for dispute resolution so
that the Center may quickly and
efficiently respond to the request: (1) A
brief but comprehensive statement of
each issue to be resolved, including a
description of the issue, the nature of
the issue (i.e., scientific, procedural, or
both), possible solutions based on
information in the administrative file,
whether informal dispute resolution
E:\FR\FM\19JYN1.SGM
19JYN1
Agencies
[Federal Register Volume 77, Number 139 (Thursday, July 19, 2012)]
[Notices]
[Pages 42500-42501]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-17554]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2011-N-0230]
Agency Information Collection Activities; Announcement of Office
of Management and Budget Approval; Examination of Online Direct-to-
Consumer Prescription Drug Promotion
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
collection of information entitled ``Examination of Online Direct-to-
Consumer Prescription Drug Promotion'' has been approved by the Office
of Management and Budget (OMB) under the Paperwork Reduction Act of
1995.
FOR FURTHER INFORMATION CONTACT: Juanmanuel Vilela, Office of
Information Management, Food and Drug Administration, 1350 Piccard Dr.,
PI50-400B, Rockville, MD 20850, 301-796-7651,
Juanmanuel.Vilela@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: On January 31, 2012, the Agency submitted a
proposed collection of information entitled ``Examination of Online
Direct-to-Consumer Prescription Drug
[[Page 42501]]
Promotion'' to OMB for review and clearance under 44 U.S.C. 3507. An
Agency may not conduct or sponsor, and a person is not required to
respond to, a collection of information unless it displays a currently
valid OMB control number. OMB has now approved the information
collection and has assigned OMB control number 0910-0714. The approval
expires on July 31, 2015. A copy of the supporting statement for this
information collection is available on the Internet at https://www.reginfo.gov/public/do/PRAMain.
Dated: July 12, 2012.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2012-17554 Filed 7-18-12; 8:45 am]
BILLING CODE 4160-01-P